Survival rates for osteosarcoma, the most common primary bone cancer, have changed little over the past three decades and are particularly low for patients with metastatic disease. We conducted a multi-institutional genome-wide association study (GWAS) to identify germline genetic variants associated with overall survival in 632 patients with osteosarcoma, including 523 patients of European ancestry and 109 from Brazil. We conducted a time-to-event analysis and estimated hazard ratios (HR) and 95% confidence intervals (CI) using Cox proportional hazards models, with and without adjustment for metastatic disease.
The results were combined across the European and Brazilian case sets using a random-effects meta-analysis. The strongest association after meta-analysis was for rs3765555 at 9p24.1, which was inversely associated with overall survival (HR 5 1.76; 95% CI 1.41-2.18, p 5 4.84 3 10 27 ). After imputation across this region, the combined analysis identified two SNPs that reached genome-wide significance. The strongest single association was with rs55933544 (HR 5 1.9; 95% CI 1.5-2.4; p 5 1.3 3 10 28 ), which localizes to the GLDC gene, adjacent to the IL33 gene and was consistent across both the European and Brazilian case sets. Using publicly available data, the risk allele was associated with lower expression of IL33 and low expression of IL33 was associated with poor survival in an independent set of patients with osteosarcoma. In conclusion, we have identified the GLDC/IL33 locus on chromosome 9p24.1 as associated with overall survival in patients with osteosarcoma. Further studies are needed to confirm this association and shed light on the biological underpinnings of this susceptibility locus.
Osteosarcoma is the most common primary bone cancer in children and adolescents. [1] [2] [3] [4] The introduction of effective neoadjuvant and adjuvant chemotherapy in the 1980s resulted in improved long-term survival for nonmetastatic osteosarcoma patients, increasing survival from 20-30% to >70%. [4] [5] [6] [7] However, over the past three decades, there has been little improvement in survival rates for patients with metastatic disease at diagnosis 8 with 5-year overall survival rates remaining at 25-30%. 9, 10 Several factors have been suggested to influence survival of patients with osteosarcoma, 11 including age at diagnosis, metastatic disease at presentation, tumor histology, blood alkaline phosphatase levels, tumor size and location and response to chemotherapy (estimated by the percentage of tumor necrosis after chemotherapy). [12] [13] [14] Recently, we reported that germline genetic variants in the NFIB gene locus (9p23-9p22.3) are associated with metastatic disease at osteosarcoma diagnosis, suggesting that genetic susceptibility could contribute to survival. 15 There is growing interest in whether germline genetic variants could influence outcomes of patients with cancer. A population-based family study showed that cancer-specific survival can be partly related to inherited factors within families, suggesting there are germline genetic determinants of survival. 16 While earlier candidate gene studies have identified variants associated with prognosis that have not been confirmed, more recent large genome-wide association studies (GWAS) have identified associations between common SNPs and survival in adult cancers of the pancreas, 17 breast, [18] [19] [20] [21] [22] [23] ovary 24 and in a rare pediatric cancer, neuroblastoma. [25] [26] [27] There have also been exploratory pharmacogenomic studies of pediatric Ewing sarcoma and osteosarcoma that have identified SNPs associated with response to treatment and survival, [28] [29] [30] [31] although most await further validation. We performed a GWAS to explore whether germline genetics may contribute to survival in patients with osteosarcoma.
Methods

Study populations
A summary of the participating studies is provided in Supporting Information, Table 1 . Previously, we reported 689 histologically confirmed osteosarcoma patients of >80% European ancestry based on an STRUCTURE analysis 32 employing principal components analyses of a set of 12,000 unlinked markers (pairwise r 2 < 0.004). 15, 33 A subset of 523
European ancestry osteosarcoma patients had available data on mortality (European set) for a survival analysis. After performing the GWAS for survival in this data set, we evaluated the most promising SNPs from the European set (p < 10 24 ) in 109 Brazilian osteosarcoma patients from the Instituto de Oncologia Pedi atrica GRAACC/UNIFESP and Universidade Federal de Sao Paulo, Brazil (Brazilian set; Supporting Information, Table 1 ). Participating subjects provided informed consent under the auspices of local Institutional Review Boards.
Genotyping and quality control
All subjects were previously genotyped as part of our osteosarcoma susceptibility GWAS (dbGaP Study Accession: phs000734.v1.p1). 33 In brief, genotyping was conducted on the Illumina OmniExpress BeadChip, SNPs included in the analyses were autosomal with a minor allele frequency (MAF) of 5% or more; had a 90% or more completion rate; and no evidence of deviation from Hardy-Weinberg equilibrium (p > 10
27
). SNPs were also excluded if they had
What's new? To date, prognostic factors associated with survival in patients with osteosarcoma are scarce. Here, the authors conducted a multi-institutional genome-wide association study to explore whether germline genetics may contribute to overall survival in osteosarcoma patients. They identified a common single nucleotide polymorphism, rs55933544, located in the GLDC gene on chromosome 9, associated with poor survival. The rs55933544 risk allele was associated with lower expression of the nearby gene, IL33. These findings, if replicated in additional populations, form the foundation for future studies of the molecular basis of the association of the GLDC/IL33 (rs55933544) variant with survival in osteosarcoma.
abnormal heterozygosity values. After quality control assessment, 510,856 SNPs were advanced in our survival analysis.
Statistical analyses
We conducted a time-to-event analysis to investigate the effect of genetic variation on overall survival. The outcome variable of interest was time until the event of death. The overall survival time was calculated as the time from the date of osteosarcoma diagnosis until the date of death for those deceased or the last date known to be alive; patients were censored at the last date known to be alive or when lost to follow-up. All events were identified and verified through medical record review and/or death certificates at each participating study center. We modeled each genome-wide association between one or more SNPs and survival using Cox proportional hazards regression and estimated hazard ratios (HR) and 95% confidence intervals (CI) per copy of the minor allele (log-additive genetic model). 34 We tested the hazards proportionality assumption (i.e., the hazard ratio is constant over time) 35 of the Cox model using Schoenfeld's residuals 36, 37 ; we did not detect nominally significant violations of the proportional hazards assumption.
Cox models were adjusted for age at diagnosis, gender, significant principal components and study/center (except for the Brazilian study, as all samples were from the same hospital). We did not adjust for metastatic disease agnostically at the genome-wide level, because some SNPs may be associated with metastatic disease and survival, as we have shown previously, 15 and thus adjusting for potential intermediate factors that lie on the causal pathway could introduce bias. [38] [39] [40] However, as metastatic disease is a prognostic factor for overall survival, 12 we performed sensitivity analyses for the top signals by also adjusting for metastatic disease. 41 We constructed Kaplan-Meier survival curves 42 for the top SNPs under dominant models and compared their statistical equivalence for each model with the log-rank test.
SNPs that reached p < 10 24 in the European set were followed up in the Brazilian set. We used a random-effects meta-analysis with inverse-variance weighting to estimate the summary effect across the sets. 43 We evaluated between-sets heterogeneity using Cochran's Q chi-squared statistic and quantified heterogeneity with the I 2 metric. 44 SNPs that demonstrated significant between-set heterogeneity (p < 0.05) were excluded.
Based on our GWAS results, we conducted region-specific imputation analysis of flanking SNPS, namely, 1 Mb region on either side of the strongest SNP using the IMPUTE2 software and the reference data from the 1000 Genomes project (Phase 3 genotype data). 45 To investigate whether signals in the same genomic region represent independent associations, we conducted conditional analyses by adjusting the Cox models for the top SNP in each region as applicable.
Statistical analyses were performed in Stata version 13 and R 3.0.2. All p values are two-sided.
eQTL and survival-expression analyses
We performed expression quantitative trait locus (eQTL)-based analyses using publicly available genotype and expression data from 29 osteosarcoma tumors (GSE33383) 46 and separately in osteosarcoma tumors from 89 patients included in the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) osteosarcoma dataset (http://ocg. cancer.gov/programs/target). 47 The data used for TARGET are available at dbGaP accession phs000218, accession phs000468, in which we conducted survival-expression analysis. 47 For the 127 patients from the combined dataset from was used to plot regional associations. Table 1 shows the characteristics of the patients included in this study. There were 632 total osteosarcoma patients included in the overall survival analyses. In the European set, there were 170 (33%) mortality events and 37 (34%) in the Brazilian set. Age (p < 0.001) and presence of metastases at diagnosis (p < 0.001) were associated with patient survival (Table 1 and Supporting Information, Fig. 1 ).
Results
Patient characteristics
SNPs associated with overall survival
In a case-case analysis, 81 SNPs were associated with overall survival at p < 10 24 in the European set (Supporting Information, Table 2 ) and were followed up in the independent set of 109 osteosarcoma cases from Brazil. The strongest association with overall survival in the European set is at chromosome 5q11.1 tagged by rs1030228 (located 14 kb 5 0 of NDUFS4) with an HR for mortality of 1.71 (95% CI 1.39-2.12, p 5 7.10 3 10
27
; Supporting Information, Fig. 2 and Table 2 ). However, this SNP is not associated with survival in the Brazilian study (p 5 0.80). There is a large degree of between-set heterogeneity (p het 5 0.052, I 2 5 73.5%) for this variant (Supporting Information, Table 2 ). In the combined analysis, the strongest association was SNP rs3765555, which is inversely associated with overall survival (HR 5 1.76 per copy of the A allele, 95% CI 1.41-2.18, p 5 4.84 3 10 27 ; I 2 5 0%; Table 2 and Fig. 1a ). This SNP is located in intron 23 of the glycine dehydrogenase (decarboxylating) gene (GLDC) on chromosome 9p24.1. The MAF for rs3765555 in the European (MAF 5 0.26) and Brazilian (MAF 5 0.21) populations are similar and we did not observe significant between-set heterogeneity (p het 5 0.34; Table 2 and Supporting Information, Table 2 ).
In a further exploration of the promising regions, we imputed SNPs across a 1 Mb region centered on rs3765555 to further evaluate this locus. After a random-effects metaanalysis for the imputed SNPs, we identified rs55933544 (Table 2 and Fig. 1a) as the SNP most strongly associated with overall survival (HR 5 1.89 per copy of the T allele, 95% CI 1.50-2.37; p 5 4.81 3 10
28
; I 2 5 0%), which is in strong LD with rs3765555 (r 2 5 0.86 in Europeans and r 2 5 0.94 in admixed Americans). The results remained the same after adjustment for metastatic disease at diagnosis (Table 2) , suggesting that the 9p24.1 locus marked by rs55933544 affects overall survival independent of metastatic disease at genomewide significance (HR 5 1.92 per copy of the T allele, 95% CI 1.53-2.41; p 5 1.34 3 10
; I 2 5 0%). rs55933544 (chr9:6534080) was not correlated with SNP rs7034162 at 9p23-9p22.3 (chr9:14190287) that we previously identified as associated with metastatic disease at osteosarcoma diagnosis (r 2 5 0.0008, 1,000 Genomes Project CEU data).
15
A second SNP at 9p24.1, rs74438701 located 25 kb downstream of the interleukin 33 (IL33) gene, is also inversely associated with overall survival in the combined analysis (HR 5 2.00 per copy of the C allele, 95% CI 1.56-2.57, p 5 4.90 3 10
28
; I 2 5 0%; Fig. 1b) . However, the conditional analysis showed that rs74438701 is not an independent signal (Fig. 1c) .
Kaplan-Meier curve analysis indicate a statistically significant difference between survival rates over time (log-rank test p < 0.001) for both the dominant (Fig. 1d) and a multiplicative model (data not shown) for rs55933544. In addition, we confirmed this association in an independent dataset of 89 cases (TARGET 47 ; log-rank p 5 0.013; Fig. 2a) . We examined the set of highly correlated surrogate SNPs (n 5 31) across the 9p24.1 region (based on an r 2 > 0.4, 1,000 Genomes Project CEU data) to identify putative regulatory elements using the ENCODE data resource 50 tools HaploReg 51 and RegulomeDB 52 (Supporting Information, Table 3 ). A subset of the surrogate SNPs (n 5 29) are located in predicted promoter and/or enhancer histone marks, DNAse sensitivity regions and/or transcription factor binding sites in a variety of different cell types and may have a functional impact (Supporting Information, Table 3 ).
IL33 expression levels associated with survival
We performed expression quantitative trait locus (eQTL) analyses to evaluate whether rs55933544 was associated with expression of GLDC, IL33 or other neighboring proteinencoding genes, using publicly available expression and genotyping data on osteosarcoma tumors. Interestingly, a previous eQTL was observed between rs55933544 and IL33 expression in human skin 54 and human brain tissue 55 (Supporting 1 All subjects included in the European set were of >80% European ancestry. 2 Shows the time at which 75% of patients had not experienced the event of interest (i.e., death or progression).
3 p values are from log-rank test. Abbreviations: ST, survival time; NA, nonapplicable. Information, Table 3 ). We found that the risk allele (T) of rs55933544 was significantly associated with a decrease in IL33 expression in both osteosarcoma tumor data sets from TARGET 47 (N 5 83, p 5 0.041) and Kuijjer et al. 46 (N 5 29, p 5 0.020) ( Fig. 2b and Supporting Information, Fig. 3 ). In addition, lower expression of IL33 in osteosarcoma tissue was independently associated with worse osteosarcoma patient survival in TARGET 47 (log-rank test p 5 0.023; Fig. 2c ) and Kuijjer et al. 46 (raw p 5 7.9 3 10
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; Supporting Information, Fig. 3 ). There was no association between rs55933544 genotypes and expression of GLDC or other nearby proteinencoding genes (TPD52L3, UHRF2 and KDM4C; data not shown).
Discussion
We conducted a genome-wide association study for overall survival in osteosarcoma cases using data from a multistage, international collaborative effort. 33 One locus, GLDC/IL33 at 9p24.1, was associated with overall survival of patients with osteosarcoma, which suggests that germline genetics can influence osteosarcoma outcomes, independent of metastatic disease. Here we observed moderate to large effect sizes for a SNP associated with overall survival, a finding similar to that observed in our GWAS of metastatic disease at osteosarcoma diagnosis. 15 The observed effect sizes are also comparable to GWAS of other pediatric and young adulthood cancers, 25, [56] [57] [58] and higher than those observed in adult GWAS of common cancer susceptibility. [59] [60] [61] The most promising signal for overall survival in patients with osteosarcoma localizes to the 9p24.1 region, downstream and independent of the NFIB gene locus (9p23-9p22.3) previously reported for metastatic disease. 15 The SNP marker, rs55933544, in the GLDC gene region is associated with decreased survival. High expression of GDLC has been associated with poor survival in other cancers 62, 63 ; however, we did not detect an eQTL for rs55933544 and GDLC in osteosarcoma cells. Interestingly, rs55933544 alleles have also been associated with expression of the nearby gene, IL33
54,55 and we detected an eQTL with IL33 in osteosarcoma cells. In addition, lower expression of IL33 was associated with poor survival in patients with osteosarcoma. IL-33 is an inhibitor of bone reabsorption, blocking osteoclastic activity, 64 which may be important in osteosarcoma. Lower levels of IL-33 have also been associated with worse prognosis or more advanced disease in several other tumor types, [65] [66] [67] consistent with our data.
This exploratory study requires further follow up and has limitations. Treatment likely varied among patients in our studies, but we could not control for this because treatment information was not available. However, it is unlikely that individual treatment modalities varied systematically by germline genotype. We also performed a combined analysis with osteosarcoma patients from Brazil, with a relatively small sample size. LD patterns differ in many parts of the genome between admixed Brazil populations and Europeans, and this could lead to false negative results in our analysis. This could explain the lack of replication in Brazilian patients of some of the top SNPs in the European osteosarcoma patients. However, an important strength is that this two-stage design also reduces the likelihood of false-positive results.
In conclusion, we provide evidence that germline genetic variants are associated with overall survival in osteosarcoma patients. These findings warrant follow-up in additional populations and functional characterization to investigate the biologic mechanisms by which polymorphisms at this locus impact survival. 
